388 related articles for article (PubMed ID: 28945887)
1. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
[TBL] [Abstract][Full Text] [Related]
4. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446
[TBL] [Abstract][Full Text] [Related]
7. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
8. Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian
Shen W; Shan B; Liang S; Zhang J; Yu Y; Zhang Y; Wang G; Bai Y; Qian B; Lu J; Jiang Z
Pathol Oncol Res; 2021; 27():581534. PubMed ID: 34257528
[No Abstract] [Full Text] [Related]
9. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.
Schrock AB; Pavlick D; Klempner SJ; Chung JH; Forcier B; Welsh A; Young L; Leyland-Jones B; Bordoni R; Carvajal RD; Chao J; Kurzrock R; Sicklick JK; Ross JS; Stephens PJ; Devoe C; Braiteh F; Ali SM; Miller VA
Clin Cancer Res; 2018 Apr; 24(8):1881-1890. PubMed ID: 29363525
[No Abstract] [Full Text] [Related]
10. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
11. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
12. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer.
Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H
Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757
[No Abstract] [Full Text] [Related]
14. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR
Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422
[TBL] [Abstract][Full Text] [Related]
15. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
17. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
[TBL] [Abstract][Full Text] [Related]
18. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
19. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
[TBL] [Abstract][Full Text] [Related]
20.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
[Next] [New Search]